Morning Overview on MSN
Daraxonrasib, a daily RAS-blocking pill, raised pancreatic cancer survival from 6.7 to 13.2 months with fewer severe side effects than chemo
Patients with metastatic pancreatic cancer who had already failed at least one round of chemotherapy lived roughly twice as ...
Morning Overview on MSN
The government just greenlit a daraxonrasib expanded-access program for pancreatic-cancer patients with the KRAS G12C mutation — opening the new targe…
For the roughly 1 to 2 percent of pancreatic-cancer patients whose tumors carry a specific genetic glitch called KRAS G12C, ...
The landmark success of a drug against an ‘undruggable’ cancer is spurring fresh optimism in the quest to treat seemingly ...
A new daily pill called daraxonrasib is showing promise against advanced pancreatic cancer in a first-in-human trial of 168 ...
A phase 3 clinical trial has demonstrated that daraxonrasib significantly improved overall survival and progression-free ...
Two nights before the data were announced, “transformative” was the word used to describe the results for RASolute 302 ...
ASCO 2026 cancer breakthroughs from Chicago include daraxonrasib nearly doubling survival in metastatic pancreatic cancer, ...
Farber's Brian Wolpin, MD, MPH, will present positive results from the RASolute 302 trial showing a substantial prolongation of survival for patients with previously treated metastatic pancreatic ...
Revolution Medicines is rated a Hold due to valuation concerns, uncertain acquisition prospects, and solo commercialization.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results